Table 7.
Odds ratios (ORs) and 95% confidence intervals (CIs) for 2011 baseline SUA associated with the prevalence of T2DM in 2011.
| N = 6,566 | Model 1 OR (95% CI) | Wald, df | p | Model 2 OR (95% CI) | Wald, df | p | Model 3 OR (95% CI) | Wald, df | p | Model 4 OR (95% CI) | Wald, df | p |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male (N = 2,962) | ||||||||||||
| Q1 (741) | Ref (1.000) | Ref (1.000) | Ref (1.000) | Ref (1.000) | ||||||||
| Q2 (744) | 0.947 (0.719,1.248) | 0.1491 | 0.699 | 0.943 (0.716,1.243) | 0.1721 | 0.679 | 0.904 (0.681,1.198) | 0.4941 | 0.482 | 0.860 (0.647,1.144) | 1.0681 | 0.301 |
| Q3 (737) | 0.863 (0.651,1.143) | 1.0591 | 0.303 | 0.857 (0.647,1.137) | 1.1451 | 0.285 | 0.827 (0.620,1.103) | 1.6671 | 0.197 | 0.759 (0.567,1.017) | 3.4161 | 0.065 |
| Q4 (740) | 1.121 (0.857,1.467) | 0.6951 | 0.404 | 1.104 (0.843,1.447) | 0.5161 | 0.473 | 1.019 (0.772,1.346) | 0.0191 | 0.892 | 0.883 (0.665,1.174) | 0.7321 | 0.392 |
| p-trend | 1.028 (0.942,1.121) | 0.3771 | 0.539 | 1.023 (0.937,1.116) | 0.2501 | 0.617 | 0.999 (0.913,1.093) | 0.0001 | 0.987 | 0.949 (0.866,1.041) | 1.2271 | 0.268 |
| Female (N = 3,604) | ||||||||||||
| Q1 (903) | Ref (1.000) | Ref (1.000) | Ref (1.000) | Ref (1.000) | ||||||||
| Q2 (899) | 0.907 (0.694,1.186) | 0.5081 | 0.476 | 0.872 (0.666,1.142) | 0.9911 | 0.319 | 0.858 (0.654,1.126) | 1.2161 | 0.270 | 0.827 (0.629,1.087) | 1.8541 | 0.173 |
| Q3 (901) | 0.967 (0.742,1.259) | 0.0631 | 0.802 | 0.916 (0.702,1.196) | 0.4151 | 0.520 | 0.895 (0.684,1.170) | 0.661 | 0.417 | 0.840 (0.641,1.101) | 1.5901 | 0.207 |
| Q4 (901) | 1.383 (1.077,1.775) | 6.4711 | 0.011 | 1.237 (0.960,1.596) | 2.6951 | 0.101 | 1.174 (0.908,1.518) | 1.5041 | 0.220 | 1.038 (0.799,1.350) | 0.0801 | 0.778 |
| p-trend | 1.136 (1.050,1.229) | 10.1101 | 0.001 | 1.099 (1.015,1.190) | 5.3881 | 0.020 | 1.075 (0.992,1.166) | 3.0981 | 0.078 | 1.033 (0.951,1.122) | 0.5981 | 0.439 |
| Total (N = 6,566) | ||||||||||||
| Q1 (1639) | Ref (1.000) | Ref (1.000) | Ref (1.000) | Ref (1.000) | ||||||||
| Q2 (1646) | 0.977 (0.809,1.179) | 0.061 | 0.807 | 0.950 (0.786,1.148) | 0.2821 | 0.595 | 0.939 (0.774,1.138) | 0.4131 | 0.520 | 0.903 (0.744,1.097) | 1.0551 | 0.304 |
| Q3 (1644) | 1.024 (0.849,1.235) | 0.0621 | 0.804 | 0.977 (0.809,1.180) | 0.0601 | 0.807 | 0.962 (0.792,1.168) | 0.1561 | 0.693 | 0.883 (0.725,1.074) | 1.5581 | 0.212 |
| Q4 (1637) | 1.255 (1.047,1.505) | 6.0381 | 0.014 | 1.169 (0.970,1.408) | 2.6931 | 0.101 | 1.149 (0.945,1.396) | 1.9441 | 0.163 | 1.012 (0.830,1.234) | 0.0141 | 0.906 |
| p-trend | 1.078 (1.017,1.143) | 6.4001 | 0.011 | 1.074 (1.007,1.144) | 4.7671 | 0.029 | 1.049 (0.983,1.119) | 2.0511 | 0.152 | 1.000 (0.936,1.068) | 0.0001 | 0.999 |
ORs, odds ratios; CIs, confidence intervals; SUA, serum uric acid; T2DM, type 2 diabetes mellitus; BMI, body mass index.
Model 1: unadjusted.
Model 2: adjusted for age, sex (total subgroup), education level, marital status, and current residence.
Model 3: adjusted for age, sex (total subgroup), education level, marital status, current residence, smoking status, alcohol consumption, social interaction, physical activity, and chronic disease.
Model 4: adjusted for age, sex (total subgroup), education level, marital status, current residence, smoking status, alcohol consumption, social interaction, physical activity, chronic disease, and BMI.
The cutoff values of baseline SUA in males: <4.051 mg/dL, 4.051 to < 4.759 mg/dL, 4.759 to < 5.648 mg/dL, ≥5.648 mg/dL.
The cutoff values of baseline SUA in females: <3.251 mg/dL, 3.251 to < 3.833 mg/dL, 3.833 to < 4.853 mg/dL, ≥4.853 mg/dL.
The cutoff values of baseline SUA in total participants: <3.533 mg/dL, 3.533 to < 4.235 mg/dL, 4.235 to < 5.085 mg/dL, ≥5.085 mg/dL.